Eye Injections for Macular Degeneration: 2025 Guide

Eye injections for macular degeneration remain the cornerstone therapy for preserving vision—especially in wet AMD. In 2025, longer-acting medicines such as Eylea HD (aflibercept 8 mg) and Vabysmo (faricimab) are helping many patients stretch the time between visits while maintaining sight, and emerging options for advanced dry AMD are expanding choices.

What are eye injections for macular degeneration?

Intravitreal injections deliver medication directly into the vitreous—the gel inside your eye—to target disease at its source. By placing the drug where it’s needed, doctors can quickly reduce fluid, swelling, and abnormal vessel growth that threaten central vision.

These injections are most often used for wet age-related macular degeneration (AMD), a form that can progress rapidly if untreated. They’ve transformed outcomes over the past decade, allowing many people to stabilize or even improve vision compared with the era before anti-VEGF therapy.

During treatment, your ophthalmologist uses antiseptic iodine and numbing drops, then gently places a tiny needle through the white part of the eye to deliver medicine. The injection itself takes seconds; most visits last 10–15 minutes. Vision checks and imaging (like OCT scans) guide how often you return.

How the medicines work

Most drugs for wet AMD block VEGF (vascular endothelial growth factor), a signal that drives leaky, fragile blood vessels under the retina. By inhibiting VEGF, medications such as Lucentis (ranibizumab), Eylea (aflibercept 2 mg), Avastin (bevacizumab, off-label), and Vabysmo (faricimab) reduce leakage and swelling to protect central vision.

Newer options aim to last longer. Eylea HD (aflibercept 8 mg) and Vabysmo were shown in pivotal trials to maintain vision with extended intervals for many patients—often every 8–12 weeks, and for some, up to 16 weeks—after initial loading doses. Your exact schedule will depend on your eye’s response and your doctor’s “treat-and-extend” plan.

Wet vs. dry AMD: where injections fit

Wet AMD

For wet AMD, anti-VEGF injections are the standard of care. Choices include Lucentis, Eylea (2 mg), off-label Avastin, Vabysmo, and Eylea HD. In real-world practice, many patients start monthly, then extend to every 8–12 weeks if the retina stays dry on OCT imaging. Some individuals can go even longer under close supervision.

Biosimilars (such as ranibizumab biosimilars) are also entering the market, potentially lowering costs while providing comparable clinical results. Ask your retina specialist whether a biosimilar is appropriate for you.

Dry AMD (geographic atrophy)

For years, dry AMD had few medical options beyond lifestyle changes and AREDS2 vitamins. That’s changing. The FDA has cleared injections that slow geographic atrophy (advanced dry AMD), including pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). These do not restore lost vision but can slow the expansion of atrophic areas, aiming to preserve reading and facial-recognition ability longer.

What’s new in 2025?

Two trends stand out: longer dosing intervals for wet AMD and the emergence of disease-modifying options for geographic atrophy. Eylea HD and Vabysmo continue to support extended intervals (often 12–16 weeks for suitable patients), reducing visit burden without compromising outcomes compared with older regimens in clinical trials like PULSAR/PHOTON (aflibercept 8 mg) and TENAYA/LUCERNE (faricimab).

Researchers are also studying combination approaches, refillable drug reservoirs, and sustained-delivery implants to further reduce injection frequency. While not everyone can extend, more patients now have a realistic chance of fewer visits with tight monitoring.

Do eye injections really help?

Yes—anti-VEGF therapy has dramatically improved the outlook for wet AMD. Large studies and real‑world data show most treated patients maintain vision, and a meaningful percentage gain letters on eye charts compared with baseline. The key is timely diagnosis and sticking with the plan your retina specialist recommends.

Benefits and drawbacks

Benefits

Proven to slow or stabilize vision loss in wet AMD; some patients improve.
Newer drugs can reduce how often you need injections (for many, 8–16 weeks after loading).
For advanced dry AMD, GA treatments offer the first FDA‑approved way to slow progression.
Office procedure is quick; most people report only mild, temporary discomfort.

Drawbacks

Ongoing therapy—often long term—plus regular monitoring visits.
Out‑of‑pocket costs can add up without adequate insurance.
Common, usually mild side effects: gritty sensation, redness, small floaters for a day or two.
Rare but serious risks include eye infection (endophthalmitis), inflammation, or retinal detachment; urgent care is needed if pain or vision worsens suddenly.

Costs and insurance coverage

Prices vary by drug and region:

Avastin (off‑label): often around $50–$100 per dose from compounding pharmacies.
Lucentis, Eylea (2 mg), Vabysmo: commonly $1,800–$2,500 per injection without insurance.
Eylea HD (8 mg): typically higher than standard Eylea; ask your clinic for current pricing.

In the U.S., Medicare Part B and many private insurers cover office‑administered AMD injections. Patients may still owe deductibles or 20% coinsurance unless they have supplemental coverage. Manufacturer copay programs or patient assistance may help eligible individuals with commercial insurance.

What to expect at your appointment

After a vision check and OCT scan, your eye is cleaned with iodine and numbed with drops or gel. A small instrument may gently hold your eyelids open. The injection goes into the white part of the eye, away from the center of vision, and takes seconds. You might see temporary bubbles or floaters afterward.

Mild irritation or tearing for a day is common. Avoid rubbing the eye, and call your doctor immediately if you develop worsening pain, increased light sensitivity, or a drop in vision—signs that could indicate infection or inflammation.

How often will I need injections?

Most wet AMD patients begin with a loading phase (often monthly for 3 months). From there, many move to “treat‑and‑extend” visits every 6–12 weeks as long as the retina stays dry. Some can stretch to 16 weeks (about 4 months) with Eylea HD or Vabysmo; others need closer intervals. For GA, dosing is typically monthly or every other month depending on the medication.

Who is a good candidate?

If you’ve been diagnosed with wet AMD—or have geographic atrophy in dry AMD—your retina specialist may recommend injections based on exam findings and imaging. People who notice new distortion, wavy lines, or a dark spot in central vision should seek prompt evaluation; early treatment helps preserve sight.

Practical tips for patients

Bring sunglasses; eyes may be light‑sensitive after the visit.
Arrange transportation the first time until you know how you feel post‑injection.
Keep all follow‑ups—even if vision seems stable—to catch early changes.
Ask about dosing intervals, imaging results, and whether you’re a candidate for extended schedules.
Discuss costs up front and explore assistance programs if needed.

Bottom line

In 2025, eye injections remain the gold standard for wet AMD and a growing option for advanced dry AMD. With newer agents enabling longer intervals for many patients, treatment is becoming less burdensome—without sacrificing results. Partner closely with your ophthalmologist to personalize a plan that protects your vision and independence.